Silvant Capital Management’s Akero Therapeutics AKRO Stock Holding History

Silvant Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,305	Closed	-$78K	–	298
2022 Q3	$78K	Sell	2,305 -1,907	-45%	-$29.2K	0.01%	273
2022 Q2	$40K	Hold	4,212	–	–	0.01%	284
2022 Q1	$60K	Hold	4,212	–	–	0.01%	268
2021 Q4	$89K	Sell	4,212 -270	-6%	-$5.99K	0.02%	236
2021 Q3	$100K	Hold	4,482	–	–	0.02%	225
2021 Q2	$111K	Hold	4,482	–	–	0.02%	225
2021 Q1	$130K	Hold	4,482	–	–	0.02%	213
2020 Q4	$116K	Hold	4,482	–	–	0.02%	217
2020 Q3	$138K	Buy	4,482 +1,684	+60%	+$58.9K	0.03%	199
2020 Q2	$70K	Buy	+2,798	New	+$63.9K	0.01%	234

Other funds holding AKRO

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Silvant Capital Management's AKRO Position: Q4 2022 in Review

Silvant Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2022, closing a stake of 2,305 shares — an estimated $78K sold.

Silvant Capital Management first reported a position in AKRO in Q2 2020 and held it in 10 quarters. The position peaked at $138K in Q3 2020. 162 funds tracked by Wall St. Rank hold AKRO as of Q4 2022.

Silvant Capital Management reported no remaining Akero Therapeutics position as of Q4 2022 after selling out during the quarter.
Silvant Capital Management sold 2,305 Akero Therapeutics shares in Q4 2022, an estimated $78K.
Silvant Capital Management first reported a position in Akero Therapeutics in Q2 2020 and held it in 10 quarters.
Silvant Capital Management's Akero Therapeutics position peaked at $138K in Q3 2020.
162 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2022.

Based on Silvant Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.